Sanofi To Test Arthritis Drug Kevzara For Coronavirus

'Scientific Rationale' Behind Regeneron-partnered IL-6 Inhibitor

The French giant is already working on a vaccine to combat COVID-19 and is now evaluating whether its rheumatoid arthritis drug Kevzara could treat pulmonary complications related to the coronavirus.

France
France's Sanofi steps up fight against COVID-19 • Source: Shutterstock

Sanofi and Regeneron Pharmaceuticals Inc. are moving swiftly to start trials to see whether their rheumatoid arthritis drug Kevzara could treat the symptoms of coronavirus.

The French drug-maker told Scrip that "there is scientific rationale that supports the exploration" of Kevzara (sarilumab), its interleukin-6 (IL-6)...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip